April 23-26, 2022
Lisbon, Portugal

32nd European Congress of Clinical Microbiology & Infectious Diseases.

Explore more information for Gilead COVID-19 therapies
Results (4)

Remdesivir treatment for COVID-19 in hospitalized children: CARAVAN interim results

COVID-19 treatment and outcomes in over 850,000 hospitalized patients in the United States: May 2020-December 2021

Outpatient remdesivir prevents COVID-19 progression in high-risk patients when randomized within 7 days from symptom onset: subanalyses from a phase 3 trial

Mortality in 2,310 renal transplant recipients hospitalized for COVID-19: renal allograft function is a clinically dominant predictor of mortality